Breakthrough badge for Novartis’ skin cancer combo
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Read More
Tag: COMBI-AD
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
